Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Ltd., has announced the successful dosing of the first patient in the United States in the expansion part of a global, multicenter Phase I clinical study of irpagratinib (ABSK-011), a highly selective small-molecule FGFR4 inhibitor for patients with FGF19 overexpression advanced hepatocellular carcinoma. Irpagratinib was previously granted Fast Track Designation by the U.S. FDA, supporting its accelerated global clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021334), on February 11, 2026, and is solely responsible for the information contained therein.